166 related articles for article (PubMed ID: 33097455)
1. Validation of the "fitness criteria" for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL).
Borlenghi E; Pagani C; Zappasodi P; Bernardi M; Basilico C; Cairoli R; Fracchiolla N; Todisco E; Turrini M; Cattaneo C; Da Vià M; Ciceri F; Passamonti F; Mancini V; Sciumè M; Cerqui E; Sciumè M; Rossi G
J Geriatr Oncol; 2021 May; 12(4):550-556. PubMed ID: 33097455
[TBL] [Abstract][Full Text] [Related]
2. Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network.
Zappasodi P; Marbello L; Borlenghi E; Fumagalli M; Bernardi M; Fracchiolla N; Mancini V; Da Vià M; Ravano E; Cerqui E; Ferretti VV; Rocca B; Calvello C; Cazzola M; Castagnola C; Rossi G
Ann Hematol; 2018 Nov; 97(11):2107-2115. PubMed ID: 30009341
[TBL] [Abstract][Full Text] [Related]
3. An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices.
Ma E; Bonthapally V; Chawla A; Lefebvre P; Swords R; Lafeuille MH; Fortier J; Emond B; Duh MS; Dezube BJ
Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):625-636.e3. PubMed ID: 27686689
[TBL] [Abstract][Full Text] [Related]
4. Adapting the Fitness Criteria for Non-Intensive Treatments in Older Patients with Acute Myeloid Leukemia to the Use of Venetoclax-Hypomethylating Agents Combination-Practical Considerations from the Real-Life Experience of the Hematologists of the Rete Ematologica Lombarda.
Rossi G; Borlenghi E; Zappasodi P; Lussana F; Bernardi M; Basilico C; Molteni A; Lotesoriere I; Turrini M; Frigeni M; Fumagalli M; Cozzi P; Gigli F; Cattaneo C; Fracchiolla NS; Riva M; Martini G; Mancini V; Cairoli R; Todisco E
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254875
[TBL] [Abstract][Full Text] [Related]
5. Azacitidine in the treatment of older patients affected by acute myeloid leukemia: A report by the Rete Ematologica Pugliese (REP).
Delia M; Carluccio P; Buquicchio C; Vergine C; Greco G; Amurri B; Melpignano A; Melillo L; Cascavilla N; Guarini A; Capalbo S; Tarantini G; Mazza P; Pavone V; Di Renzo N; Specchia G
Leuk Res; 2015 Aug; ():. PubMed ID: 26364798
[TBL] [Abstract][Full Text] [Related]
6. Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy
Miyamoto T; Sanford D; Tomuleasa C; Hsiao HH; Olivera LJE; Enjeti AK; Gimenez Conca A; Castillo TBD; Girshova L; Martelli MP; Guvenc B; Delgado A; Duan Y; Garbayo Guijarro B; Llamas C; Lee JH
Leuk Lymphoma; 2022 Apr; 63(4):928-938. PubMed ID: 35147482
[TBL] [Abstract][Full Text] [Related]
7. The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the "Rete Ematologica Lombarda".
Molteni A; Riva M; Borin L; Bernardi M; Pelizzari AM; Freyrie A; Della Porta M; Nichelatti M; Ravano E; Quaresmini G; Mariotti J; Caramazza D; Ubezio M; Guarco S; Gigli F; Greco R; Cairoli R; Morra E
Leuk Res; 2016 Mar; 42():21-7. PubMed ID: 26852003
[TBL] [Abstract][Full Text] [Related]
8. [The prognostic effects of two comprehensive geriatric assessment methods in elderly patients with acute myeloid leukemia].
Zhang S; Feng R; Li JT; Wang T; Zhang CL; Bai JF; Li Y; Shao RY; Liu H
Zhonghua Nei Ke Za Zhi; 2021 Oct; 60(10):880-885. PubMed ID: 34551476
[No Abstract] [Full Text] [Related]
9. Assessing eligibility for treatment in acute myeloid leukemia in 2023.
Venditti A; Cairoli R; Caira M; Finsinger P; Finocchiaro F; Neri B; De Benedittis D; Rossi G; Ferrara F
Expert Rev Hematol; 2023 Mar; 16(3):181-190. PubMed ID: 36876439
[TBL] [Abstract][Full Text] [Related]
10. Definition of Unfit for Standard Acute Myeloid Leukemia Therapy.
Klepin HD
Curr Hematol Malig Rep; 2016 Dec; 11(6):537-544. PubMed ID: 27681539
[TBL] [Abstract][Full Text] [Related]
11. Real-World Treatment Patterns and Clinical Outcomes in Korean Patients With AML Ineligible for First-Line Intensive Chemotherapy: A Subanalysis of the CURRENT Study, a Non-Interventional, Retrospective Chart Review.
Bang SM; Kang KW; Song IC; Llamas C; Duan Y; Jeong JY; Lee JH
J Korean Med Sci; 2023 Nov; 38(44):e345. PubMed ID: 37967874
[TBL] [Abstract][Full Text] [Related]
12. [The prognosis value of comprehensive geriatric assessment in elder patients with acute myeloid leukemia in a single center].
Bai JF; Mei D; Han HX; Zhang S; Feng R; Li JT; Wang T; Zhang CL; Ning SY; Liu H
Zhonghua Xue Ye Xue Za Zhi; 2019 Mar; 40(3):200-203. PubMed ID: 30929386
[No Abstract] [Full Text] [Related]
13. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
14. Assessment of an embedded primary care-derived electronic health record (EHR) frailty index (eFI) in older adults with acute myeloid leukemia.
Cheng JJ; Tooze JA; Callahan KE; Pajewski NM; Pardee TS; Reed DR; Klepin HD
J Geriatr Oncol; 2023 Sep; 14(7):101509. PubMed ID: 37454532
[TBL] [Abstract][Full Text] [Related]
15. Geriatric perspective: how to assess fitness for chemotherapy in acute myeloid leukemia.
Klepin HD
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):8-13. PubMed ID: 25696829
[TBL] [Abstract][Full Text] [Related]
16. Secondary acute myeloid leukaemia in elderly patients: Patient's fitness criteria and ELN prognostic stratification can be applied to guide treatment decisions. An analysis of 280 patients by the network rete ematologica lombarda (REL).
Borlenghi E; Pagani C; Zappasodi P; Bernardi M; Basilico C; Todisco E; Fracchiolla N; Mancini V; Turrini M; Da Vià M; Sala E; Cattaneo C; Petullà M; Serana F; Ferrario A; Cairoli R; Cortelezzi A; Santoro A; Castagnola C; Rossi G
Am J Hematol; 2018 Feb; 93(2):E54-E57. PubMed ID: 29164738
[No Abstract] [Full Text] [Related]
17. Clinical outcome of older adults with acute myeloid Leukemia: An analysis of a large tertiary referral Center over two decades.
Ihlow J; Gross S; Neuendorff NR; Busack L; Herneth A; Singh A; Schwarz M; Flörcken A; Anagnostopoulos I; Türkmen S; Burmeister T; Blau IW; Bullinger L; Westermann J
J Geriatr Oncol; 2021 May; 12(4):540-549. PubMed ID: 33223482
[TBL] [Abstract][Full Text] [Related]
18. Real-World Treatment Patterns and Clinical Outcomes in Canadian Patients with AML Unfit for First-Line Intensive Chemotherapy.
Sanford D; Desjardins P; Leber B; Paulson K; Assouline S; Lembo PMC; Fournier PA; Leitch HA
Curr Oncol; 2022 Sep; 29(10):6794-6806. PubMed ID: 36290812
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
Filì C; Candoni A; Zannier ME; Olivieri J; Imbergamo S; Caizzi M; Nadali G; Di Bona E; Ermacora A; Gottardi M; Facchinelli D; Ciancia R; Lazzarotto D; Dubbini MV; Festini G; Gherlinzoni F; Michieli MG; Semenzato G; Fanin R
Leuk Res; 2019 Jan; 76():33-38. PubMed ID: 30529681
[TBL] [Abstract][Full Text] [Related]
20. Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with acute myeloid leukemia meeting ineligibility criteria for high intensity chemotherapy.
Li S; Ji Y; Peng Y; Kota V; Kim C
Leuk Lymphoma; 2022 Jan; 63(1):131-141. PubMed ID: 34643153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
